
Alpha Cognition Inc. Announces $35 Million Oversubscribed Public Offering of Common Shares
Alpha Cognition Inc, a commercial‑stage biopharmaceutical enterprise committed to advancing therapies for neurodegenerative diseases, today announced the successful pricing of an oversubscribed underwritten public offering of its common shares. Under the terms of the offering, the Company is issuing 5,600,000…












